Impact of malignancy on clinical outcomes in patients with acute coronary syndromes

Yousif, Nooraldaem; Niederseer, David; Davies, Allan; Issa, Meidi El; Sidia, Besma; Noor, Husam A; Amin, Haitham; Räber, Lorenz; Gencer, Baris; Klingenberg, Roland; Windecker, Stephan; Mach, François; Matter, Christian M.; Nanchen, David; Lüscher, Thomas F.; Obeid, Slayman

doi:10.1016/j.ijcard.2020.12.010

Cited by 5 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ACS are associated with significantly higher mortality and morbidity rates in cancer patients than in their non-cancer counterparts [ 51 ]. Yousif et al, in their prospective study, reported a higher all-cause mortality rate at 12 months, 30.3% in cancer vs. 11.9% in non-cancer patients, p < 0.0001, along with a higher incidence of net adverse clinical events, 33.9% in cancer patients vs. 19.8% in non-cancer patients, p < 0.001 [ 52 ]. Mrtozek et al showed that troponin-positive ACS (HR 2.365 [1.162–4.817], p = 0.018) was most predictive of mortality in cancer patients presenting with ACS.…”

Section: Approach To Coronary Artery Disease Diagnosis and Managementmentioning

confidence: 99%

Coronary Revascularization in Patients With Cancer

Pushparaji

Donisan

Balanescu

et al. 2023

Curr Treat Options Cardio Med

View full text Add to dashboard Cite

Purpose of review The treatment of coronary artery disease (CAD) in cancer patients is an evolving landscape. Recent data emphasizes the importance of aggressive management of cardiovascular risk factors and diseases in improving cardiovascular health in this unique group of patients regardless of cancer type or stage. Recent findings Novel cancer therapeutics such as immune therapies and proteasome inhibitors have been associated with CAD. Recent stent technologies may safely allow for shorter duration (< 6 months) of dual antiplatelet therapy post-percutaneous coronary interventions. Intracoronary imaging may be useful in the decision making process in terms of stent positioning and healing. Summary Large registry studies have partially filled a gap left by the lack of randomized controlled trials in the treatment of CAD in cancer patients. Cardio-oncology is gaining traction as a major sub-specialty in the cardiology field given the release of the first European Society of Cardiology — Cardio-oncology guidelines in 2022.

show abstract

Section: Approach To Coronary Artery Disease Diagnosis and Managementmentioning

confidence: 99%